Ketamine Analogues Modulate GABAa Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents targeting the cerebellum are limited, and ketamine, while effective, has significant side effects such as vivid dreams and cognitive disruptions due to its action on α6β2/3δ GABAA receptors, necessitating the development of alternative compounds that can modulate these receptors with reduced side effects.
Innovation Solution
Development of ketamine analogues, including oxime derivatives, which selectively modulate α6β2/3δ GABAA receptors while maintaining blocking action on NMDA receptors, potentially offering improved therapeutic efficacy with reduced hallucinogenic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ketamine is used to modulate α6β2/3δ GABAA receptors and block NMDA receptors, then therapeutic effects are achieved, but side effects such as vivid dreams, illusions, and cognitive disruptions occur
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of ketamine through analogues and derivatives (changing molecular parameters) to achieve differential receptor binding profiles. This allows maintaining NMDA receptor blockade while reducing GABAA receptor modulation, thereby preserving therapeutic effects while minimizing side effects
Solution Approach 2:
The patent applies local quality by designing compounds with selective affinity for specific receptor subtypes. The ketamine analogues are engineered to have preferential binding to NMDA receptors over GABAA receptors, creating localized specificity in drug-receptor interaction that reduces off-target effects while maintaining desired therapeutic action
2Manufacturing precision
If ketamine selectively modulates α6β2δ and α6β3δ GABAA receptors, then granule neuron excitability is impacted, but hallucinogenic effects and cognitive disruptions occur
Solution Approach 1:
The patent uses parameter changes by modifying molecular structure parameters of ketamine to create analogues with altered receptor binding characteristics. This structural parameter optimization achieves high selectivity for NMDA receptors while minimizing interaction with GABAA receptors, thereby eliminating hallucinogenic effects
Solution Approach 2:
The patent applies copying by creating ketamine analogues that replicate the desirable NMDA receptor blocking action while copying and modifying the molecular features responsible for GABAA receptor interaction. This selective copying allows preservation of therapeutic mechanism while eliminating harmful side effects
Data Source
AI summary
Embodiments of the present disclosure provide compositions including ketamine analogs, salts, and disalts, pharmaceutical compositions including ketamine analogs, salts, or disalts, methods of treatment of a condition or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.